RxDoctor Payments Data

Peter Strutz, MD

Internal Medicine · Fallbrook, CANPI 1417913328

Payments from drug & device makers

$1,163in general payments, 2019–2025

Across 72 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$535
  • AbbVie$129
  • Johnson & Johnson$108
  • Amgen$92
  • Novo Nordisk$76
  • Kowa Pharmaceuticals America, Inc.$47
  • plus $174 from 7 others

What the payments were for

  • Food & beverage$1,163100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,163 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$172,849
Medicare patients
310
Services billed
2,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate57$62,291
EliquisApixaban44$51,856
JardianceEmpagliflozin29$30,303
XareltoRivaroxaban20$29,156
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$14,795
JanumetSitagliptin Phos/Metformin Hcl11$13,199
OzempicSemaglutide14$12,718
Combivent RespimatIpratropium/Albuterol Sulfate12$6,716
InvokanaCanagliflozin11$6,396
PremarinEstrogens, Conjugated16$5,165
Levothyroxine Sodium339$4,716
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide121$4,516
Atorvastatin Calcium415$3,803
Memantine Hcl21$3,312
LantusInsulin Glargine,hum.Rec.Anlog19$3,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$24$57,02160 claims
Johnson & JohnsonXarelto, Invokana$108$35,55231 claims
GSKTrelegy Ellipta$22$14,79513 claims
Novo NordiskOzempic$76$12,71814 claims
AbbVieSynthroid$129$2,25641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fallbrook

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →